Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valsartan + rosuvastatin is a fixed-dose combination of two small molecule drugs used for the concomitant treatment of hypertension and hyperlipidemia. Valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by selectively inhibiting the angiotensin II type 1 (AT1) receptor, thereby blocking vasoconstriction and aldosterone-secreting effects of angiotensin II. Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced plasma LDL cholesterol levels. The combination provides additive benefits in lowering both blood pressure and LDL cholesterol compared to either drug alone, with studies showing efficacy and safety in patients with coexisting hypertension and dyslipidemia[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valsartan + rosuvastatin.